OS in patients with HIV-associated MCD stratified according to MCD treatment. When patients receiving rituximab only (R Mono) or receiving R + C were compared with patients receiving cytostatic therapy (with or without antiviral agents; C(+V) only), there was a significant effect on OS toward rituximab-based regimens. The mean estimated OS of patients with R or R + C was not reached, compared with 5.1 years (P = .03) in patients receiving C(+V).